Products >> Molecular Biology & Diagnostics >> Reagents & Kits >>
Quantitative Molecular Kits for Oncohematology
.............................................................................................................................................................................................
 

Ipsogen has developed a comprehensive range of quantitative assays for AML; ALL and MPD1 including CML allowing a sensitive and quantitative measurement of circulating abnormal genes to monitor the treatment response and disease evolution in leukemia patients. All Ipsogen products are developed and manufactured in regulatory compliant facilities and many are registered as CE marked IVD2. In 2007 Ipsogen is applying for ISO 13485 accreditation. Our products are available today in over 40 countries thanks to a professional manufacturing and marketing organization, and a reliable distribution network. 

Ipsogen R&D efforts are based on internal research and international collaborations. In Europe, Ipsogen is an active player in collaborative networks such as EAC3, ELN4, CONTICANET5 and COBRED6.
 

Janus Tyrosine Kinase 2
JAK2

JAK2 MutaQuant ™ Kit is a research tool intended for the accurate quantification of JAK2 mutant (V617F) and wild type alleles and determination of allele load in human genomic DNA.

Reference

Name

MQPP-01

JAK2 MutaQuant™ Kit

     
 

JAK2 MutaScreen Kits for V617F mutation screening

Kits allow the detection and estimation of % JAK2 V617F mutation from genomic DNA isolated from whole peripheral human blood. This test improves the classification of Philadelphia Negative (Ph-) myeloproliferative diseases.

Reference

Name

MSPP-01

JAK2 MutaScreen™ Kit

MSPP-02

JAK2 MutaScreen™ Mini Kit

MSPP-03

JAK2 MutaScreen™ Kit & Reference Scale

FusionQuant®,

Ipsogen FusionQuant® Kits are unique molecular kits providing standardisation and accurate quantification of fusion gene transcripts in Leukemia. These ready to use kits contain primers & probes mixes and standards specific for the fusion gene and the ABL control gene. Most of our kits are CE marked and can be used for In Vitro Diagnostic use. CE marking of the full FusionQuant® Kits range will be completed soon.

FusionQuant® Kits

As of December 7 2003, all reagents used for the purpose of diagnosis, monitoring or treatment of disease must conform to the European in vitro diagnostic medical device directive (98/79/EC). The proof of compliance of such a product is the CE mark. To comply with these new regulations, Ipsogen now offers CE marked FusionQuant® Kits for monitoring therapy efficiency and disease relapse.

Reference

Name

Cytogenetic Abnormality

FQPP-01

AML1-ETO

t(8;21)

FQPP-02

CBFb-MYH 11 A

Inv(16)

FQPP-05-CE*

PML-RAR bcr1

t(15;17)

FQPP-06

PML-RAR bcr2

t(15;17)

FQPP-07

PML-RAR bcr3

t(15;17)

FQPP-09-CE*

BCR-ABL e1a2 mbcr

t(9;22)

FQPP-09-ABL

BCR-ABL e1a2 mbcr

t(9;22)

FQPP-09-GUS

BCR-ABL e1a2 mbcr

t(9;22)

FQPP-09-BCR

BCR-ABL e1a2 mbcr

t(9;22)

FQPP-10-CE*

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-10-ABL

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-10-GUS

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-10-BCR

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-10M-CE* (Mega Kit)

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-10M-ABL (Mega Kit)

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-10M-GUS (Mega Kit)

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-10M-BCR (Mega Kit)

BCR-ABL b3a2 Mbcr

t(9;22)

FQPP-11

TEL – AML1 e4e11

t(12;21)

 

NPM1,

MutaQuant™ standards are intended to provide calibration for the quantification of individual single polymorphism by RQ-PCR and are available for specific detection of polymorphisms from both RNA (MQRS) and genomic DNA (MQRS-G) samples.
Each MutaQuant™ Gene Standard is comprised of five vials containing precisely controlled dilutions of a given mutated gene to serve as a calibrator for RQ-PCR.

Reference

Name

MQRS-01*

Npm1 Mutation A

MQRS-02*

Npm1 Mutation B and D

MQRS-01G+

Npm1 Mutation A

MQRS-02G+

Npm1 Mutation B and D

.............................................................................................................................................................................................